Gossamer Bio Stock Earnings Reports

Key points for investors:

- Clinical/regulatory: Phase III PROSERA showed a placebo-adjusted improvement in 6-minute walk distance of 13.3 meters at Week 24 (seralutinib +28.2 m vs placebo +13.5 m; p=0.032). The result met traditional statistical significance (p<0.05) but did not meet the prespecified alpha (0.025). All four key secondaries favored seralutinib and a stronger effect was seen in a prespecified risk-enriched subgroup. Management believes the totality of evidence (PROSERA + Phase II TORREY + mechanistic imaging) supports an NDA under the “one adequate and well-controlled study + confirmatory evidence” framework.

- Imaging/mechanism: The prespecified CT FRI substudy (162 enrolled, 125 paired scans) demonstrated multi-compartment structural reverse remodeling (arterial, venous, fibrosis-like parenchymal features and vascular complexity) that correlated with clinical endpoints (6MWD, NT-proBNP, REVEAL Lite 2). Management positions these imaging data as mechanistic/confirmatory evidence that seralutinib affects remodeling biology (PDGFR/CSF1R/c-KIT) beyond vasodilation.

- Regulatory timing: Company secured an in-person Type B pre-NDA meeting with FDA in mid-June; briefing book submitted. Management’s current NDA target is September 2026 (subject to meeting outcome). If timeline proceeds as expected, potential approval could follow in Q3 2027.

- Financial/capital structure: Cash and marketable securities were $99M as of March 31, 2026; runway expected to extend to Q1 2027 under current plans. The company implemented a significant reduction in force and broad cost containment to lower burn. Management executed a proposed exchange of $200M 2027 convertible notes into a combination of equity, new secured convertible notes and warrants (on full subscription reduces outstanding convertible debt to $72M, extends maturity to 2030, new notes bear 7.5% cash interest and are secured; the exchange requires ~98% participation). These actions aim to remove overhang and preserve resources for NDA execution and potential commercialization.

- Commercial/strategic view: Management believes seralutinib’s novel mechanism and imaging-supported structural effects differentiate it from current PAH vasodilators and could support earlier or broader use across risk spectrums; label language and exact positioning to be discussed with FDA (imaging may appear in pharmacodynamics section if accepted).

- Risks/uncertainties: Top-line PROSERA p-value did not meet the prespecified alpha; imaging results are nominal and exploratory; cash runway is limited; NDA timing and approval depend on FDA feedback and final analyses.